Scientists have found a way to turn on a gene that is abnormally switched off in Friedreich's ataxia, a debilitating neurodegenerative disease. The discovery, made at St. Jude Children's Research Hospital in the United States, shows that silenced genes are not locked away as firmly as once thought. Instead, the packaging around DNA can be penetrated by a specially designed chemical adapter, which delivers activating proteins to the gene inside.
A Surprising Looseness in Gene Packaging
Cells silence genes by wrapping DNA tightly around proteins called histones. This packaging was believed to be a solid barrier, but the new research reveals it can behave more like molasses under certain conditions. The chemical adapter moves through this semi-fluid packaging, allowing gene-activating proteins to reach the silenced frataxin gene. This process successfully reactivated the gene in laboratory experiments, offering a fresh approach to treating Friedreich's ataxia.
The study, published in Nature Cell Biology, challenges a long-held assumption about how histone modifications work. Scientists previously thought these chemical changes acted in a simple on-off binary manner. The new findings suggest a more nuanced mechanism, where the packaging's fluidity can be exploited to access genes that are turned off.
What This Means for Friedreich's Ataxia
Friedreich's ataxia is caused by the silencing of the frataxin gene, which leads to progressive damage to the nervous system. Patients often lose the ability to walk and may develop heart problems. The St. Jude team's work is still in early stages, but it opens a potential path for therapies that directly reactivate the silenced gene. Local researchers and patient advocacy groups have shown keen interest, as current treatments only manage symptoms rather than address the root cause.
The discovery also has broader implications for epigenetics, the study of how genes are regulated without changes to the DNA sequence. By showing that silenced genes can be accessed and reactivated, the research may inspire new strategies for other diseases where gene silencing plays a role, such as certain cancers.
A New Understanding of Gene Control
The findings shift how scientists view the physical state of DNA packaging. Rather than a rigid block, the packaging appears to have a dynamic quality that can be harnessed. This could lead to more targeted interventions, where specific genes are switched on without affecting others. The St. Jude team is now exploring how this adapter works in living organisms, though those results are not yet available.
For now, the study stands as a proof of concept that silenced genes are not permanently inaccessible. It offers hope for Friedreich's ataxia patients and adds a new layer of complexity to the field of gene regulation. The research was funded by St. Jude and other organizations, and the team plans to continue investigating the therapeutic potential of this approach.
